Methods of inhibiting osteoclast activity

Details Methods of inhibiting osteoclast activity Methods of inhibiting osteoclast activity

2011-08-23

2011-08-23

Padmanabhan, Paddy (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S748000, C514S182000, C514S172000

Reexamination Certificate

active

08003628

ABSTRACT:
Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5470952 (1995-11-01), Stahl et al.
patent: 5849865 (1998-12-01), Cheng et al.
patent: 5869452 (1999-02-01), Ng et al.
patent: 5955425 (1999-09-01), Morley et al.
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6171860 (2001-01-01), Baker et al.
patent: 6239157 (2001-05-01), Mbalaviele
patent: 6673771 (2004-01-01), Greene et al.
patent: 7566741 (2009-07-01), Greene et al.
patent: 0 045 665 (1982-02-01), None
patent: 0 784 093 (1997-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/53842 (1998-12-01), None
patent: WO 99/58674 (1999-11-01), None
patent: WO 00/01349 (2000-01-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 01/08699 (2001-02-01), None
Ahmed et al., The Journal of Biological Chemistry, 250(21):8477-8482, Nov. 1975.
Albericio et al., Int. J. Peptide Protein Res. 26:92-97, 1985.
Anderson et al. Nature, vol. 390, pp. 175-179, Nov. 13, 1997.
Banner et al., Cell, 73:431-445, May 1993.
Beutler et al., Science, 264:667-668, Apr. 1994.
Beutler et al., Annals of The New York Academy of Sciences, 730:118-133, 1994.
Bowie et al. Science, vol. 247, pp. 1306-1310, 1990.
Brisson et al., Nature, 310:511-514, Aug. 1984.
Broglie et al., Science 224:838-843, May 1984.
Bucay et al., Genes Dev., 12(9):1260-1268, 1998.
Cole et al., Monoclonal Antibodies and Cancer Therapy, 77-96, Jan.-Feb. 1985.
Coruzzi et al., The EMBO Journal 3(8):1671-1679.
Cote et al., Proc. Natl. Acad. Sci. USA, 80:2026-2030, 1983.
Doring et al., Molecular Immunology, 31(14):1059-1067, 1994.
Filvaroff, Current Biology, 8:R679-682, 1998.
Fox et al. Biochem. Biphys. Res. Comm., vol. 276, pp. 868-872, 2000.
Fingl et al., “General Principles,” In: The Pharmacological Basis of Therapeutics, Chapter 1, 1-46, 1975.
Fuller, K., et al., “Trance is necessary and sufficient for osteoblastmediated activation of bone resorption in osteoclasts,” Database Chemical Abstracts on STN, No. 129:314804, Abstract, J. Exp. Med., 1998, 188(5), 997-1001.
Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995.
Gurley, et al., Molecular and Cellular Biology, 6:559-565, Feb. 1986.
Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973.
Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982.
Holladay et al., Tetrahedron Letters, 24(41):4401-4404, 1983.
Houghten et al. Cell, vol. 93, pp. 165-176, Apr. 17, 1998.
Houghten et al., Vaccines 86, Cold Spring Harbor Laboratory, pp. 21-25, 1986.
Hruby et al., Life Sciences, 31:189-199, 1982.
Hudson et al. Int. J. Protein Res., 14:177-185, 1979.
Huse, et al., Science, 246:1275-1281, Dec. 1989.
Jennings-White et al., Tetrahedron Letters, 23(25):2533-2534, 1982.
Kamber et al., Helvetica Chimica Acta, 63(Fasc. 4):899-915, 1980.
Kitazawa et al., J. of Clinical Investigation, 94:2397-2407, Dec. 1994.
Kobayashi et al., J. Exp. Med., vol. 191, No. 2, 275-285, 2000.
Kohler et al., Nature, 256:495-497, 1975.
Kong et al., Immunology and Cell Biology, 77:188-193, Jan. 1999.
Kong et al., Nature, 397:315-323, 1999.
Kornak et al., Cell, 104:205-215, 2001.
Kozbor et al., Immunology Today, 4(3):72-79, 1983.
Lacey et al., Amer. J. of Pathology, 157(2):435-448, 2000.
Li Y.P. et al., Nature Genetics, 23:447-451, 1999.
Li J. et al., PNAS, 97(4):1566-1571, 2000.
Livingstone, David M., Methods in Enzymology, Affinity Techniques, 723-731, 1974.
Logan et al., Proc. Natl. Acad. Sci. USA, 81:3655-3659, Jun. 1984.
Mackett et al., Proc. Natl. Acad. Sci. USA 79:7415-7519, Dec. 1982.
Mackett et al., Journal of Virology, 49(3):857-864, Mar. 1984.
McOsker et al., J. Bone & Mineral Research, Twelfth Annual Meeting of the American Societ for Bone and Mineral Research, 5(Supp 2):S105, No. 128, Abstract, Aug. 28-31, 1990.
Moore et al., Techniques in Protein Chemistry VII, Marsak (ed.) 81-91, 1996.
Morley, J.S., Trends Pharm. Sci., 463-468, Dec. 1980.
Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855, Nov. 1984.
Mortensen et al., J. Clinical Endrocrinology and Metabolism, 83(2):396-402, 1998.
Nakagawa, N., e tal., “Rank is the essential signaling receptor for osteoclast differentiation factor in osteoclastogensis” Database Chemical Abstracts on STN, No. 130:166173, Abstract, Biochem. Biophys. Res. Commun., 1998, 253(2), 395-400.
Neuberger et al., Nature, 312:604-608, Dec. 1984.
Nicholson et al., J. Clinical Investigation, 78:355-360, Aug. 1986.
Panicali et al., Proc. Natl. Acad. Sci. USA, 79:4927-4931, Aug. 1982.
Peppel et al., J. Exp. Med., 174:1483-1489, Dec. 1991.
Ponder et al., J. Mol. Biol., 193:775-791, 1987.
Scimeca, J.C., Bone, 26(3):207-213, 2000.
Shalhoub, V. et al., British J. of Haematology, 111:501-512, 2000.
Shalhoub et al., J. Cellular Biochem., 72(2):251-261, 1999.
Sietsema et al., Drugs Exptl. Clin. Res., XV(9):389-396, 1989.
Simonet et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, 1997, vol. 89, pp. 309-319.
Singer et al., J. Clinical Endocrinology and Metabolism, 83(6):1906-1910, 1998.
Siris et al., J. Bone and Mineral Research, 13(6):1032-1038, 1998.
Smith et al., Journal of Virology, 46:584-593, May 1983.
Spatola, A. F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, 7:267-357, 1983.
Spatola et al., Life Sciences, 38:1243-1249, 1986.
Suda et al., Endocrine Reviews 20(3):345-357, Jun. 1999.
Suda et al., Novartis Found Symp, 232: 235, 2001 (Abstract).
Takamatsu et al., EMBRO Journal, 6(2):307-311, 1987.
Takasaki et al., Nature Biotechnology, 15:1266-1270, 1997.
Takeda et al., Nature 314:452-454, 1985.
Tam et al., Synthesis, 955-957, Dec. 1979.
Van Beek E., J. Bone and Mineral Research, 11(10):1492-1497, 1996.
Weitzmann et al., J. of Bone and Mineral Research, 16(2):328-337, 2001.
Williams et al., Immunology, 84:433-439, 1995.
Wong et al. Journal of Leukocyte Biology, 65:715-724, Jun. 1999.
Yamaguchi et al., J. of Biological Chemisty, 273(9):5177-5123, Feb. 28, 1998.
Yasuda et al. Proc. Natl. Acad. Sci. USA., vol. 95 pp. 3597-3602, Mar. 1998.
Zhang et al., Nature Biotechnology, 14:472-475, Apr. 1996.
Zhang et al., Nature Biotechnology, 15:150-154, 1997.
Wong, B.R. et al., “Trance (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell-specific Survival Factor,” J. Exp. Med., Dec. 15, 1997, 186(12), 2075-2080.

Affiliated with

Also associated with

Rating

Methods of inhibiting osteoclast activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting osteoclast activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting osteoclast activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630340